Mechanism of action
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. DNA gyrase introduces negative supercoils into DNA, allowing the double helix to unwind during replication. Topoisomerase IV separates daughter DNA molecules after replication.
By binding to these enzymes, ciprofloxacin stabilizes the enzyme-DNA complex and prevents the re-ligation of DNA strands, leading to double-strand breaks and ultimately bacterial cell death. This mechanism is bactericidal.
Ciprofloxacin demonstrates concentration-dependent killing and a post-antibiotic effect, meaning bacterial growth suppression continues even after drug levels fall below the minimum inhibitory concentration (MIC).
Spectrum of activity
Ciprofloxacin has excellent activity against gram-negative organisms, including Pseudomonas aeruginosa, Enterobacteriaceae (E. coli, Klebsiella, Proteus, Enterobacter), Haemophilus influenzae, Moraxella catarrhalis, and Neisseria species. It also covers atypical respiratory pathogens such as Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila.
Gram-positive coverage is less reliable. While ciprofloxacin has some activity against Staphylococcus aureus, it is not the first-line choice for MRSA. Streptococcus pneumoniae and other streptococci show variable susceptibility, and fluoroquinolones are generally avoided for empiric pneumococcal pneumonia due to resistance concerns.
Ciprofloxacin is also active against certain intracellular pathogens, including Salmonella, Shigella, and Campylobacter species.
- Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, causing bactericidal double-strand DNA breaks.
- Black box warning: tendon rupture (especially Achilles tendon) in patients >60 years or on corticosteroids; discontinue if tendon pain develops.
- Black box warning: potentially irreversible peripheral neuropathy; stop immediately if symptoms (pain, burning, tingling) occur.
- Contraindicated in myasthenia gravis due to risk of exacerbating muscle weakness (black box warning).
- Excellent gram-negative coverage including Pseudomonas aeruginosa; poor gram-positive coverage (not reliable for MRSA or Streptococcus pneumoniae).
- Avoid in children except for specific indications (complicated UTI, anthrax prophylaxis) due to arthropathy risk in developing cartilage.
- Divalent/trivalent cations (antacids, calcium, iron) chelate ciprofloxacin and reduce absorption; separate administration by 2-6 hours.
- QT prolongation risk; avoid with other QT-prolonging drugs and in patients with uncorrected electrolyte abnormalities.
Indications
Ciprofloxacin is FDA-approved for multiple bacterial infections, though the FDA recommends reserving fluoroquinolones for infections where no alternative exists due to serious adverse effects.
Common indications
- Urinary tract infections: Complicated and uncomplicated UTIs caused by susceptible organisms, including pyelonephritis. However, increasing E. coli resistance limits empiric use in some regions.
- Prostatitis: Chronic bacterial prostatitis, as ciprofloxacin achieves good prostatic tissue penetration.
- Gastrointestinal infections: Traveler's diarrhea, infectious diarrhea caused by Shigella, Salmonella, or Campylobacter. Also used for typhoid fever.
- Respiratory infections: Acute exacerbations of chronic bronchitis, hospital-acquired pneumonia, and ventilator-associated pneumonia (especially when Pseudomonas is suspected). Not first-line for community-acquired pneumonia due to inadequate pneumococcal coverage.
- Bone and joint infections: Osteomyelitis caused by gram-negative organisms.
- Skin and soft tissue infections: Complicated infections, particularly with gram-negative involvement.
- Anthrax: Post-exposure prophylaxis and treatment of inhalational anthrax (Bacillus anthracis).
- Gonococcal infections: Previously used for uncomplicated gonorrhea, but widespread resistance now precludes routine use.
Ophthalmic and otic formulations
Topical ciprofloxacin is used for bacterial conjunctivitis, corneal ulcers, otitis externa, and chronic suppurative otitis media.
Pharmacokinetics
Ciprofloxacin is available in oral and intravenous formulations with excellent bioavailability.
- Absorption: Oral bioavailability is approximately 70-80%. Food slightly delays absorption but does not significantly affect overall bioavailability.
- Distribution: Widely distributed into tissues and body fluids, including prostate, lung, bone, and macrophages. Ciprofloxacin achieves therapeutic concentrations in most tissues, but CNS penetration is limited (10-20% of serum levels).
- Metabolism: Partially metabolized in the liver to active metabolites, but the majority is excreted unchanged.
- Excretion: Primarily renal (40-50% unchanged in urine) and fecal (15-25%). Dose adjustment is required in renal impairment.
- Half-life: Approximately 4 hours in patients with normal renal function.
Ciprofloxacin exhibits concentration-dependent pharmacodynamics. The AUC/MIC ratio and Cmax/MIC ratio are predictors of efficacy.
Adverse effects
Ciprofloxacin carries multiple black box warnings from the FDA due to serious adverse effects.
Black box warnings
- Tendinitis and tendon rupture: The Achilles tendon is most commonly affected. Risk is increased in patients over 60 years, those taking corticosteroids, and organ transplant recipients. Tendon rupture can occur during treatment or months after discontinuation.
- Peripheral neuropathy: Potentially irreversible sensory or sensorimotor neuropathy can occur rapidly. Symptoms include pain, burning, tingling, numbness, or weakness. Discontinue immediately if symptoms develop.
- CNS effects: Seizures, increased intracranial pressure (including pseudotumor cerebri), toxic psychosis, tremors, anxiety, confusion, hallucinations, and depression. Risk is increased in patients with CNS disorders or those taking NSAIDs.
- Exacerbation of myasthenia gravis: Fluoroquinolones may worsen muscle weakness in patients with myasthenia gravis. Use is contraindicated in this population.
- Aortic aneurysm and dissection: Increased risk, particularly in elderly patients, those with hypertension, or those with connective tissue disorders (e.g., Marfan syndrome, Ehlers-Danlos syndrome).
Common adverse effects
- Gastrointestinal: Nausea, diarrhea, vomiting, abdominal pain (10-15% of patients). Pseudomembranous colitis (C. difficile) is a serious complication.
- Hepatotoxicity: Transient elevation of liver enzymes; rarely, acute hepatic necrosis.
- QT prolongation: Ciprofloxacin can prolong the QT interval, increasing the risk of torsades de pointes, particularly in patients with other risk factors (hypokalemia, hypomagnesemia, concomitant QT-prolonging drugs).
- Photosensitivity: Increased risk of severe sunburn. Patients should avoid excessive sun exposure and use sunscreen.
- Arthropathy in children: Cartilage damage observed in juvenile animals. Use in pediatrics is restricted to specific indications (e.g., complicated UTI, inhalational anthrax).
- Dysglycemia: Both hypoglycemia and hyperglycemia, particularly in diabetic patients.
Hypersensitivity reactions
Rash, pruritus, urticaria, angioedema, and anaphylaxis can occur. Stevens-Johnson syndrome and toxic epidermal necrolysis are rare but serious.
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to ciprofloxacin or other fluoroquinolones
- Concomitant use with tizanidine (risk of severe hypotension and sedation)
- Myasthenia gravis (black box warning)
Relative contraindications and warnings
- Pregnancy: Category C. Fluoroquinolones cross the placenta and are generally avoided during pregnancy due to concerns about fetal cartilage development. Use only if benefits outweigh risks and no safer alternative exists.
- Breastfeeding: Ciprofloxacin is excreted in breast milk. Potential risks to the infant include arthropathy and disruption of normal flora. The American Academy of Pediatrics considers it usually compatible with breastfeeding, but caution is advised.
- Pediatric use: Reserved for specific indications due to arthropathy concerns. FDA-approved for complicated UTI, pyelonephritis, and post-exposure anthrax prophylaxis in children.
- Renal impairment: Dose adjustment required. Risk of crystalluria at high doses; maintain adequate hydration.
- Hepatic impairment: Use with caution; monitor liver function.
- Seizure disorders: Fluoroquinolones lower the seizure threshold. Use cautiously in patients with epilepsy or other CNS conditions.
- QT prolongation: Avoid in patients with known QT prolongation, uncorrected electrolyte abnormalities, or those taking other QT-prolonging drugs.
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Risk of hemolytic anemia.
- Connective tissue disorders: Avoid due to increased risk of aortic aneurysm and dissection.
Drug interactions
Ciprofloxacin has numerous clinically significant drug interactions.
Major interactions
- Tizanidine: Contraindicated. Ciprofloxacin inhibits CYP1A2, significantly increasing tizanidine levels and causing severe hypotension and sedation.
- Theophylline: Ciprofloxacin inhibits theophylline metabolism, increasing serum levels and risk of toxicity (seizures, arrhythmias). Monitor theophylline levels closely.
- Warfarin: Enhanced anticoagulant effect. Monitor INR closely and adjust warfarin dose as needed.
- Antacids, sucralfate, multivitamins, dairy products: Divalent and trivalent cations (calcium, magnesium, aluminum, iron, zinc) chelate ciprofloxacin and reduce absorption. Administer ciprofloxacin at least 2 hours before or 6 hours after these products.
- QT-prolonging drugs: Additive QT prolongation with class IA and III antiarrhythmics (e.g., amiodarone, sotalol, quinidine), macrolides, antipsychotics, and tricyclic antidepressants.
- NSAIDs: Increased risk of CNS stimulation and seizures when combined with fluoroquinolones.
- Corticosteroids: Increased risk of tendon rupture.
- Oral hypoglycemics: Altered blood glucose levels; monitor closely in diabetic patients.
- Methotrexate: Ciprofloxacin may reduce renal clearance of methotrexate, increasing toxicity risk.
- Cyclosporine: Transient elevations in serum creatinine; monitor renal function.
- Probenecid: Decreases renal clearance of ciprofloxacin, increasing serum levels.
CYP450 interactions
Ciprofloxacin is a moderate inhibitor of CYP1A2 and may increase levels of drugs metabolized by this enzyme (e.g., clozapine, ropinirole, duloxetine).
Clinical pearls
- Pseudomonas coverage: Ciprofloxacin is one of the few oral antibiotics with activity against Pseudomonas aeruginosa, making it valuable for certain UTIs, osteomyelitis, and cystic fibrosis exacerbations.
- Achilles tendon rupture: Classic USMLE presentation is an elderly patient on corticosteroids who develops sudden heel pain after starting ciprofloxacin. Discontinue immediately.
- Anthrax prophylaxis: Ciprofloxacin is first-line for post-exposure prophylaxis of inhalational anthrax.
- Avoid in children: Reserved for serious infections (e.g., complicated UTI, anthrax) due to arthropathy concerns. This is a high-yield testing point.
- Resistance patterns: Increasing fluoroquinolone resistance in E. coli, Neisseria gonorrhoeae, and Campylobacter limits empiric use. Always check local antibiograms.
- Not for streptococcal pharyngitis: Inadequate coverage of group A Streptococcus. Never use for strep throat.
- Bioavailability: Oral bioavailability is excellent (~70-80%), making IV-to-PO conversion straightforward for step-down therapy.
- C. difficile risk: Like all broad-spectrum antibiotics, ciprofloxacin increases the risk of C. difficile infection.
- Crystalluria: Rare but possible at high doses or in alkaline urine. Maintain adequate hydration.
- FDA restrictions: In 2016, the FDA issued safety alerts recommending that fluoroquinolones be reserved for patients who lack alternative treatment options for uncomplicated UTI, acute bacterial sinusitis, and acute exacerbation of chronic bronchitis due to the risk of disabling and potentially permanent side effects.
FLUOROQUINOLONES adverse effects: Fuse cartilage damage (kids), Lengthens QT, Upset stomach (GI effects), Oh no! tendons rupture, Raised LFTs (hepatotoxicity), disOrientation/CNS effects, QUinolones lower seizure threshold, In sun = photosensitivity, Neuropathy (peripheral), Old people at risk, Lowers glucose or raises it (dysglycemia), hEmolysis in G6PD deficiency, Sodium antacids block absorption.
Practice questions
1. A 68-year-old man with chronic obstructive pulmonary disease is admitted for pneumonia and started on ciprofloxacin. He is also taking prednisone for a COPD exacerbation. Three days later, he develops sudden-onset severe pain in his right heel while walking. On examination, there is swelling and tenderness over the Achilles tendon, and he cannot plantarflex his foot against resistance. Which of the following best explains this patient's presentation?
2. A 45-year-old woman with myasthenia gravis presents to the emergency department with dysuria and flank pain. Urinalysis shows pyuria and bacteriuria, and a diagnosis of acute pyelonephritis is made. Which of the following antibiotics should be avoided in this patient?
3. A 10-year-old boy is diagnosed with a complicated urinary tract infection caused by Pseudomonas aeruginosa. The infectious disease team recommends ciprofloxacin. The parents express concern about using this antibiotic in their child. Which of the following best explains the rationale for ciprofloxacin use in this patient despite typical age restrictions?
Frequently asked questions
How does ciprofloxacin work?
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and repair. By stabilizing the enzyme-DNA complex, it prevents DNA re-ligation, causing double-strand breaks and bacterial cell death. This mechanism is bactericidal and concentration-dependent. Ciprofloxacin has broad gram-negative coverage, including Pseudomonas aeruginosa, but limited gram-positive activity.
What are the side effects of ciprofloxacin?
Common side effects include nausea, diarrhea, and headache. Serious adverse effects carry black box warnings: tendon rupture (especially Achilles tendon), potentially irreversible peripheral neuropathy, CNS effects (seizures, psychosis), exacerbation of myasthenia gravis, and aortic aneurysm or dissection. Other significant risks include QT prolongation, C. difficile colitis, photosensitivity, and dysglycemia. Use is restricted in children due to cartilage damage concerns.
Can I take ciprofloxacin with dairy products or antacids?
No, avoid taking ciprofloxacin with dairy products, antacids, or supplements containing calcium, magnesium, aluminum, iron, or zinc. These divalent and trivalent cations chelate ciprofloxacin in the gastrointestinal tract, significantly reducing absorption and effectiveness. Take ciprofloxacin at least 2 hours before or 6 hours after consuming these products to ensure adequate drug levels.
Why is ciprofloxacin avoided in children?
Ciprofloxacin is generally avoided in pediatric patients because animal studies showed cartilage damage and arthropathy in developing joints. The FDA restricts pediatric use to specific serious infections where benefits outweigh risks: complicated urinary tract infections, pyelonephritis, and post-exposure anthrax prophylaxis. This is a high-yield exam topic, as fluoroquinolones should not be used for routine pediatric infections.
Ciprofloxacin vs levofloxacin — what is the difference?
Both are fluoroquinolones, but levofloxacin is a third-generation agent with better gram-positive coverage, including Streptococcus pneumoniae, making it more suitable for community-acquired pneumonia. Ciprofloxacin has superior Pseudomonas aeruginosa coverage and is preferred for urinary tract infections and gastrointestinal infections. Both share similar adverse effects including tendon rupture and peripheral neuropathy. Levofloxacin has slightly better bioavailability and once-daily dosing.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: J01MA02WHO ATC/DDD index: S01AE03
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.